Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A Combination Therapy for Asthma

Abstract: Despite the wide range of available therapies, asthma remains uncontrolled in 40-65% of patients for a number of different reasons. Treatment with an inhaled corticosteroid (ICS) is rec-ommended in the Global Initiative for Asthma 2021 report for patients across all asthma severities, with treatment options combining an ICS with a long-acting β2-agonist (LABA) or a LABA and a long-acting muscarinic antagonist (LAMA), depending on disease severity. Based on this, the avail-ability of a single inhaler fixed-dose ICS/LABA/LAMA combination is a major need in asthma management. Indacaterol acetate/glycopyrronium bromide/mometasone furoate has been developed as a once-daily inhaled asthma treatment that combines an ICS (mometasone furoate), a LABA (in-dacaterol acetate), and a LAMA (glycopyrronium bromide) in a formulation delivered using the dry powder inhaler Breezhaler®, for patients with uncontrolled asthma on medium- or high-dose ICS/LABA. This article provides an overview of the different and complementary mechanisms of action and the clinical effectiveness of the monocomponents of the indacaterol/glycopyrronium/ mometasone furoate fixed combination and highlights the benefits of using the three agents in com-bination in patients with moderate and severe asthma.